Related Experiment Video
Updated: Mar 3, 2026
Early Pathological and Magnetic Resonance Detection of Cerebral Injury Using a Rat Model of Neonatal Hypoxic Ischemic Encephalopathy
Published on: October 28, 2022
Neuroprotective Treatments after Perinatal Hypoxic-Ischemic Brain Injury Evaluated with Magnetic Resonance
Hester Rijkje Berger1, Eva Brekke, Marius Widerøe
1Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Insights
New treatments are needed for perinatal hypoxic-ischemic brain injury. Magnetic resonance spectroscopy (MRS) can track metabolic changes and evaluate neuroprotective agents, guiding future clinical trials for this condition.
Area of Science:
- Neuroscience
- Biochemistry
- Medical Imaging
Background:
- Perinatal hypoxic-ischemic (HI) brain injury is a significant health concern requiring improved treatments.
- Therapeutic hypothermia is a current treatment, but adjuvant therapies are needed to enhance neuroprotection.
- Understanding HI pathophysiology reveals targets for neuroprotection, including energy metabolism, excitotoxicity, oxidative stress, calcium homeostasis, and apoptosis.
Purpose of the Study:
- To review neuroprotective pharmacological agents evaluated using magnetic resonance spectroscopy (MRS).
- To highlight the role of MRS in observing metabolic changes post-HI and treatment effects.
- To guide future clinical trials using MRS biomarkers for perinatal brain injury.
Main Methods:
- Review of studies evaluating neuroprotective agents with 1H/31P/13C MRS.
- Noninvasive monitoring of cerebral metabolic changes following hypoxia-ischemia (HI).
- Assessment of metabolic effects of pharmacological interventions using MRS.
Main Results:
- MRS can noninvasively monitor metabolic alterations in the brain after HI.
- Various neuroprotective agents have been assessed using MRS.
- MRS provides insights into how these agents impact cerebral metabolism.
Conclusions:
- Adjuvant neuroprotective treatments are crucial for perinatal HI brain injury.
- MRS is a valuable tool for evaluating the efficacy of neuroprotective agents by monitoring metabolic changes.
- Translational MRS biomarkers can inform the design of future clinical trials for HI neuroprotection.
Abstract:
Perinatal hypoxic-ischemic brain injury is a major health problem. Adjuvant treatments that improve the neuroprotective effect of the current treatment, therapeutic hypothermia, are urgently needed. The growing knowledge about the complex pathophysiology of hypoxia-ischemia (HI) has led to the discovery of several important targets for neuroprotection. Early interventions should focus on the preservation of energy metabolism, the reduction of glutamate excitotoxicity and oxidative stress, the maintenance of calcium homeostasis, and the prevention of apoptosis. Delayed interventions should promote injury repair. The multiple metabolic changes following HI as well as the metabolic effects of potential treatments can be observed noninvasively by magnetic resonance spectroscopy (MRS). This mini-review provides an overview of the neuroprotective pharmacological agents that have been evaluated with 1H/31P/13C MRS. A better understanding of how these agents influence cerebral metabolism and the use of relevant translational MRS biomarkers can guide future clinical trials.
